Approval · Notice of Compliance 35736 · 2025
AREXVY: Notice of Compliance 35736
Issued July 21, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35736
- Date
- July 21, 2025
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additional manufacturing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AREXVY | Not yet assigned | — |
Medicinal ingredients
- RESPIRATORY SYNCYTIAL VIRUS PREFUSION F PROTEIN (RSVPREF3) 120 MCG per 0.5ML